IMTX vs. BCRX, RLAY, MESO, RGNX, CRGX, AUTL, HLVX, KYTX, NVAX, and TARS
Should you be buying Immatics stock or one of its competitors? The main competitors of Immatics include BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Mesoblast (MESO), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), Autolus Therapeutics (AUTL), HilleVax (HLVX), Kyverna Therapeutics (KYTX), Novavax (NVAX), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "biological products, except diagnostic" industry.
Immatics (NASDAQ:IMTX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.
BioCryst Pharmaceuticals received 452 more outperform votes than Immatics when rated by MarketBeat users. However, 71.43% of users gave Immatics an outperform vote while only 66.43% of users gave BioCryst Pharmaceuticals an outperform vote.
BioCryst Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 166.67%. Given BioCryst Pharmaceuticals' higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Immatics.
Immatics has higher earnings, but lower revenue than BioCryst Pharmaceuticals. Immatics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
64.4% of Immatics shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.4% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Immatics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.
BioCryst Pharmaceuticals has a net margin of -68.36% compared to Immatics' net margin of -179.67%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Immatics' return on equity.
In the previous week, BioCryst Pharmaceuticals had 45 more articles in the media than Immatics. MarketBeat recorded 46 mentions for BioCryst Pharmaceuticals and 1 mentions for Immatics. BioCryst Pharmaceuticals' average media sentiment score of 0.52 beat Immatics' score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
Summary
BioCryst Pharmaceuticals beats Immatics on 13 of the 17 factors compared between the two stocks.
Get Immatics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immatics Competitors List
Related Companies and Tools
